Background: To evaluate the impact of eHealth on disease activity, the need for hospital contacts, and medical adherence in children and adolescents
I
nflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are characterized by periods of relapse and remission. As a consequence, patients are treated during both active and inactive phases to achieve and maintain remission. Children and adolescents with IBD experience multiple challenges posed by their disease: unpredictable symptoms, a continuous need for medication and frequent visits to the hospital, all of which are associated with increased risk of school absence 1 and deterioration of quality of life (QoL). [2] [3] [4] In addition, puberty is a vulnerable period with a high risk of developing social disabilities due to the disease. 5 It is crucial for successful treatment (i.e., control of inflammation) that patients acquire insight into their disease, and understand the importance of adhering to the recommended maintenance treatment regime. 6 Despite nonadherence being a major risk factor for experiencing a relapse and increasing the risk of acute hospitalization and surgery, both adult and pediatric patients often fail to comply with the continuous medication. Nonadherence is reported in up to 75%-85% of adolescent patients. 7 Taking all this into account, there is a special need to improve adherence to therapy and provide support and education in the pediatric and adolescent patient groups, without increasing their frequency of hospital visits.
In previous work by our group, [8] [9] [10] [11] [12] [13] we have investigated the use of eHealth, that is, a self-managed interactive web-based disease monitoring tool, in adult patients with IBD. The eHealth solution www.constant-care.com was developed to individualize treatment and optimize patients' self-management, adherence, QoL, and to reduce patients' dependency on doctors. The structure of the eHealth tool was based on a traffic light system (red, yellow, and green) visualizing patient-reported symptoms in combination with the level of fecal calprotectin (FC) in a total inflammation burden score (TIBS). Depending on the TIBS, patients were guided through the traffic light system in changing their treatment if needed. In a large randomized study of patients with UC (N ¼ 333), the eHealth solution showed shortened time of relapse and improved medical adherence, disease knowledge, and QoL. 12 One study has investigated the use of eVisit, that is, clinical visits performed through a computerized interface, to facilitate communication and follow-up visits after a flare-up in pediatric IBD. 14 No study, to our knowledge, has evaluated patientadministered eHealth treatment in children and adolescents with IBD. We believe that this treatment concept would be readily taken up by pediatric and adolescent patients, for whom web communication is already a familiar part of their daily lives. On the basis of the adult version, www.constant-care.com, we developed a new eHealth program, www.young.constant-care.com, oriented toward pediatric/adolescent patients with IBD to monitor disease activity, medication, adherence, school attendance, and QoL. This eHealth solution was designed with 2 components, for nonbiological-treated patients and for biological-treated patients. The structure of the web design differed mainly according to the level of monitoring, that is, a monthly control (nonbiological) versus a weekly control (biological).
The primary aim of this study was to evaluate the impact of eHealth on disease activity, the need for hospital contacts, and the medical adherence in children and adolescents with IBD treated with nonbiological medication. The secondary aim was to assess the impact of eHealth on school attendance and quality of life. Because of the novelty of the program, the patients' use and evaluation of eHealth were recorded. This article includes the nonbiological group. Patients on biological treatment were included in a separate study with a different eHealth-and study-design.
MATERIALS AND METHODS

Study Hypothesis
eHealth, including a single annual planned control visit, might improve adherence and/or QoL, and reduce school absence without compromising disease control.
Study Design and Patients
This was an open-labeled, randomized controlled (1:1) trial of an intervention using patient-managed eHealth (web-based disease monitoring) among pediatric patients with IBD. Eligible participants were children and adolescents, 10 to 17 years old, diagnosed with UC or CD as verified by Porto criteria 15 and followed in the outpatient clinic at the Pediatric Department, Hvidovre University Hospital. The Porto criteria for the diagnosis of IBD are based on a "combination of history, physical and laboratory examination, esophagogastroduodenoscopy and ileo-colonoscopy with histology, and imaging of the small bowel." 15 To meet inclusion criteria, the patient should have received nonbiological treatment (oral and/or topical treatment) or no treatment. Exclusion criteria were insufficient Danish language skills, no access to the internet, low intellectual capacity, growth retardation, and biological treatment. Recruitment took place from September 1, 2013 to April 31, 2014. Eligible patients were invited to participate by letter or by their health care provider during regular consultations. Enrolled patients were randomized in an open fashion to either the eHealth group (web group) or to the control group for a study period of 2 years. Patients were consecutively randomized by closed envelopes representing one of the 2 groups. The envelopes were handled by a person not involved in the study group and blinded to the person enrolling patients.
On the basis of the adult eHealth web program; www. constant-care.com, [8] [9] [10] [11] [12] the pediatric/adolescent version, www. young.constant-care.com, was developed. Pediatric symptom scores were implemented, and therefore the TIBS algorithm based on symptom score and level of FC was redesigned in cooperation with 2 experienced pediatric gastroenterologists (A. P., V.W.) and 1 experienced adult gastroenterologist (P.M.). Based on the TIBS algorithm, guidelines for the patients were developed. Additional pediatric QoL and school absence measures were implemented in the web program. Weight and height measures, to ensure proper follow-up on growth, were added as well. In the program, a message tool was available for enabling the patient to write to the IBD team and receive answers in return (principal investigator or IBD-nurse) regarding nonacute questions. The message tool was developed because young people, in our experience, do not use email as frequently as adults. The text (i.e., information about disease and instructions) on the homepage was written for young people, and the homepage was designed by a professional graphic designer to appeal to young people.
Procedures
Web Intervention
Patients randomized to the web group received a personal username and a log-in for the homepage, www.young.constantcare.com, and were instructed by the principal investigator face to face for 45 minutes, 1 patient at a time, in using the web program. Education was directed toward the patient, but parents/caregivers were also present during the session. Families were instructed to consult a doctor if alarm symptoms appeared (.6 stools per day, daily fresh blood in each defecation, fever, severe abdominal pain, or/and acute-to-severe exacerbation of symptoms). The patients in both groups could at any time during the study period contact their IBD nurse/doctor as usual, if it was felt needed by the patient or relatives.
Every month, the patients with UC and CD were required to record data for the Pediatric Ulcerative Colitis Activity Index (PUCAI) 16 and the abbreviated Pediatric Crohn's Disease Activity Index 17 (abbrPCDAI), respectively, using the web program. In addition, every third month, the patient forwarded a fecal sample through mail for the analysis of FC, [18] [19] [20] and blood samples were drawn at the local laboratory. The symptom score and FC level were combined into the TIBS (range 0-10), and all 3 (symptom score, FC, and TIBS) values were visualized in a traffic light system (red, yellow, and green) in the web program for the patient. Depending on the scores, and thus the color of the traffic light, different guidelines were given to the patient (Figs. 1 and 2 ). Patients received automatically generated text message reminders through their smartphones before each deadline for data entry or blood or stool sample delivery. Parents could receive these reminders too, if they wished.
Patients were only seen in the outpatient clinic on request (on-demand outpatient visits), guided by the traffic light system, in addition to 1 annual planned visit. To ensure proper follow-up, "web-rounds" were performed weekly by the IBD-team (principal investigator or IBD-nurse supervised by gastropediatric specialized doctors). "Web-rounds" included follow-up on new web-entries from the patients, FC levels, blood test results, and ensuring that the patient/parents had contacted the hospital if indicated by the traffic light color. If blood test results required further intervention, the patient/parents were contacted directly by telephone, but if the tests were normal the results were communicated to the patient through the web program. Weight and height were monitored and if weight loss and/or growth stagnation occurred, the patient/parents were contacted. HRQoL (IMPACT III questionnaire), 21, 22 self-rated medical adherence (MARS and visual analog scale; VAS), [23] [24] [25] and self-reported days of school absence were obtained every third month.
Control Patients
Patients in the control group were monitored according to the hospital's IBD care guidelines (i.e., national pediatric IBD standard care in Denmark), with outpatient visits every third month, including blood samples and FC. In addition to normal attendance, patients completed MARS and VAS, PUCAI/abbrPCDAI, days of school absence since the last visit, and IMPACT III questionnaires.
Ethical Considerations
The trial was approved by the Danish Ethical Committee (Jr H-2-2013-061), the Danish Data Protection Agency (Jr HVH-2014-004), and was registered on www.clinicaltrials.gov in May 2013 (ClinicalTrials.gov Identifier: NCT01860651). All patients and their guardians gave written consent before study inclusion.
Outcome Measures
Primary Outcomes
Disease activity. Medication (type, dose) and step-up in treatment intensity (escalating dose or change/addition of a more potent drug) were obtained from the patient's medical record during the study period, as a proxy of progression in disease activity.
Patients in both the eHealth and control groups were instructed to self-report symptoms using the Pediatric Ulcerative Colitis Activity Index (PUCAI) or abbreviated Pediatric Crohn's Disease Activity Index (abbrPCDAI). Both are validated pediatric symptom-based disease activity indices (range between 0-85 and 0-60 points, respectively). Disease activity is categorized as following: PUCAI: ,10, none; 10 to 34, mild; 35 to 64, moderate; .64, severe; 16 and abbrPCDAI: ,10, none; 10 to 15, mild; 16 to 25, moderate; .25, severe. 17 In the abbrPCDAI, the last item includes an examination of the abdomen. Patients in the web group learned during the education session how to self-assess the abdomen and how to recognize tenderness and an abdominal mass. Patients in the control group completed the questionnaire in the waiting area before consultation with their health care provider, and due to practicalities in the waiting area, it was not possible for the patient to lie down to self-examine the abdomen. Therefore, the last item was assessed by the patient's health care provider during consultation.
FC is a stable protein released from leucocytes and is a sensitive marker of inflammation in the intestine. [18] [19] [20] The FC analyses were performed by enzyme-linked immunosorbent assay (Calpro Ltd., Lysaker, Norway), either manually or using a Dynex system. To monitor disease activity and medication side effects, the following routine blood tests were measured: C-reactive protein, erythrocyte sedimentation rate, orosomucoid, red and white blood cell counts, thrombocytes, albumin, amylase, liver function tests, creatinine, and vitamin D.
Contacts to the hospital. From the patient's medical record, the following information was obtained during the study period: outpatient visits (number), hospitalizations (number, type, and length), phone calls to doctor and nurses (number), endoscopic and imaging procedures (type and number).
Medical adherence. The Medication Adherence Report Scale (MARS) is a medication adherence self-reported tool and consists of 5 items concerning medication intake: I alter the dose/I forget to use it/I stop taking it for a while/I decide to miss out on a dose/I take less than instructed. Answers were given on a 5-point Likert scale (range 5-25 points). 23 The adherence VAS is a 10-cm long line representing a spectrum from "always" taking medicine to "never" doing so. 24, 25 The patients set a mark on the line, representing how often they take the medicine. A score of or above 80% in both the MARS and VAS indicates that the patient is adherent to the treatment.
Secondary Outcomes
School absence and HRQoL. Days of school absence were self-reported by the patient in a preprinted form. IMPACT III is a self-reported HRQoL questionnaire developed by the Pediatric IBD working group, quality of life. 22 The questionnaire consists of 35 items divided according to 6 domains: Bowel symptoms, Systemic symptoms, Emotional functioning, Social functioning, Body Image, and Treatment. Answers were given on a 5-point Likert scale (range . No precise cutoffs exist for poor or high levels of HRQoL, but a higher score represents a higher HRQoL performance. Before this study, the questionnaire was translated into Danish and implemented in the web application in cooperation with the Pediatric IBD working group of quality of life through a "Trans-Cultural-adaptation" method. 26 Use and evaluation of the eHealth program. Adherence to the eHealth program was prospectively registered by the IBD team as the number of actual entries of symptom scores and FC samples when compared with the number of entries expected. The eHealth program deliberately did not make it possible for the patient to deliver an incomplete symptom score, and therefore all registrations were fully completed.
At the end of the project, a patient-parent tandem evaluation questionnaire of 13 items on a 5-point Likert scale was collected from the web group. The questionnaire was delivered to participants on paper. Questions addressed both the patient's and parents' experience of using the eHealth program and concerned the following issues: feeling of safety and satisfaction, knowledge gained', management and understanding of IBD, worries about the disease during trial, and recommendation of the eHealth tool to others.
Data Analysis
Power calculation was made on the basis of a mean Medication Adherence Report Scale (MARS) score of 20.67; SD 4.01. 23 Using a power of 80%, a significance level of 5%, and an actual difference of three on the MARS scale, 58 participants were needed.
Data were analyzed as intention to treat. Because of the nonparametric distribution of outpatient visits, hospitalizations, and phone calls to doctors and nurses, the Wilcoxon sum rank test was used to compare the web and control groups. T-test was used to compare the absence from school between the 2 groups. To account for the longitudinally collected data, alterations during the observed period comparing the web and control groups regarding disease activity (symptom score, blood test, and FC), medical adherence, and HRQoL were analyzed using a mixed-effect model (MEM). MEM models included a random patient effect and a fixed effect interaction between group and time, to evaluate difference between the groups over time. Further adjustment variables that were included are listed below for the specific models. Time to drop out, first on-demand visit, and step-up in treatment were analyzed by Kaplan-Meier survival analysis. P value ,0.05 was considered as significant. Statistical analyses were performed using SAS Enterprise Guide 7.1 and the statistical computing program R 3. 
RESULTS
Inclusion
During the inclusion period of 8 months, and from a total of 99 eligible patients, 53 patients were included and randomized to either the web (n ¼ 27) or control group (n ¼ 26). Follow-up data are shown in Figure 3 . Demographic data for both groups are shown in Table 1 . We found no significant differences in the drop out of patients after inclusion or in the total number of days of participation when comparing web and control groups (Kaplan-Meier analysis: log rank P value ¼ 0.25).
Primary Outcome
Disease Activity
The time to first step-up in treatment intensity did not differ between the web and control groups (Fig. 4) , confirming that the eHealth intervention did not negatively interfere with treatment quality. In total, 607 symptom scores (439 web, 168 control) and 280 FC (158 web, 122 control) were collected. The MEM analysis corrected by disease type (UC/CD) revealed no difference between web and control patients in disease activity based on symptom scores. The same MEM analysis, adjusted by age and disease type, showed no difference in FC levels. The following blood analyses were collected: 323 C-reactive protein (158 web, 165 control), 296 orosomucoid (136 web, 160 control), and 310 erythrocyte sedimentation rate (148 web, 162 control). No differences in C-reactive protein, orosomucoid or erythrocyte sedimentation rate were found using the MEM when comparing web and control groups during the observation period.
Contacts to the Hospital
The number of total outpatient visits in the web group was 85 (median 2, interquartile range 2-3) and in the control group was 185 (median 8, interquartile range 4-9) (P value # 0.0001) ( Table 2 ). The number of extra outpatient visits (the on-demand visits), that is, in addition to the annual visit in the web group and the quarterly visits in the control group showed no differences; neither did time to first on-demand visit differ (log rank P value 0.395). The number of hospitalizations was not significantly different between the 2 groups, but a tendency to fewer hospitalizations in the web group was apparent (P value ¼ 0.13), Table 2 . No difference was seen in use of imaging diagnostic tests (web/ control: gastroscopy, 5/3; ileocolonoscopy, 4/6; magnetic resonance imaging [small bowel], 3/4; ultrasonography of abdomen, 2/1; and capsule endoscopy, 1/1) or numbers of phone calls to doctor or nurse.
Medical Adherence
Medical adherence represented by the MARS and VAS scores during the study period showed no difference between the 2 groups using the MEM when adjusted for age and time from diagnosis. The mean baseline of MARS in the web group was 
Secondary Outcome
School Absence and HRQoL
A significant difference was observed in the number of IBDrelated days of absence from school between the web (mean 1.6 days per patient, SEM 0.5) and the control groups (mean 16.5 days per patient, SEM 4.4; P value ¼ 0.002). In total, 335 IMPACT III questionnaires were answered: web 167 (UC 117, CD 50), control 168 (UC 84, CD 84). Mean score at baseline showed no statistically significant difference: web 149 (SEM 2.8; 95% CI, 144-155), control 145 (SEM 1.9; 95% CI, 141-149). Using the MEM adjusted for sex and age at inclusion, there was no difference in the alterations of IMPACT III score during the observation period when comparing the web and control groups. Looking at sub-scores regarding the 6 domains (Bowel symptoms, Systemic symptoms, Emotional functioning, Social functioning, Body Image, and Treatment), only Emotional functioning scored a significantly lower HRQoL in the web group (P value ¼ 0.03; Estimate 20.003 per day; 95% CI, 20.006 to 20.0003).
Use and Evaluation of the eHealth Program
Adherence to using the web program as directed was 81% (in total 384 of the 475 expected entries were obtained). The median number of extra text messages or phone call reminders in excess of the automatically generated was 4 (range 0-17): 1 patient had 17, 2 patients had 9 to 11, 9 patients had 5 to 8, and 15 patients had #4 extra text messages. Regarding outpatient visits, the control group completed 87% (146 of the 168 expected) and the web group 100% (38 of the 38 expected). We have not compared the study groups for adherence to outpatient visits as the control group patients were expected to show up to outpatient visits every third month, whereas the web group only once a year.
The final evaluation questionnaires after 2 years of participation were completed by 93% (14) in the web group and 83% (15) in the control group. None of the patients or parents felt insecure or unsafe using the web-system. Seventy-eight percentage (patients) and 69% (parents) would recommend using the Website to others; 21% (patients) and 31% (parents) were neutral; and none answered that they would not recommend it. After participating in the web project, 50% of the patients felt that they had a better understanding and knowledge of their own disease. This was confirmed by 53% of the parents.
DISCUSSION
This study is the first interactive patient-administered eHealth disease monitoring trial in pediatric and adolescents patients with IBD with a focus on the use of eHealth. The homepage, young.constant-care.com, was developed and tested for the first time in this study and represents an innovation for optimizing care in a challenged patient group.
Main Results
In this open-label randomized controlled trial, we demonstrated that self-managed eHealth is feasible and safe in children and adolescents with IBD. Without causing an increase in disease activity or escalating treatment, we found that patients monitored by the eHealth program needed fewer outpatient visits when compared with those undergoing standard care. Medical adherence was comparable in both groups, but the web group experienced less absence from school when compared with the control group. HRQoL did not differ between the 2 groups.
Safety and Usability of eHealth
It has been established that patients' disease knowledge and focus on adherence to treatment can improve chronic disease outcome [27] [28] [29] and that self-management can individualize and optimize patient care. 30 In our study, we found that despite fewer outpatient visits and an enhanced patient monitoring responsibility (self-management) in the intervention group, no increases in disease activity or treatment were seen. In fact, a tendency to fewer hospitalizations was found. The adherence to the web program was .80%. This shows that pediatric and adolescent patients can use eHealth to monitor their IBD and that the use of the web application is feasible and safe. Insights into, and knowledge of, their disease are key elements of self-management, and half of the patients reported that these elements had improved after 2 years of participation. We did not find an improvement in medical adherence in the intervention group. Results from adult IBD eHealth studies have shown divergent results regarding adherence, where Cross et al 31 reported no change, whereas Pedersen et al 9 and Elkjaer et al 12 found an enhanced adherence. In our eHealth study, adherence levels at baseline in the web and control groups were high, with little room for improvement. The high baseline reflects the limitations of self-reported medical adherence as the only measure of medical adherence, as patients are likely to report a falsely high adherence rate. This is emphasized by the high nonadherence rates (75%-85% among adolescents) found in studies using objective measures, that is, Medication Event Monitoring Systems (MEMS). 7 The measure of adherence should preferably be measured using both self-reported and objective measures, that is, a pill-count, MEMS, or blood level amounts of the treatment drug. However, in this self-administered eHealth study, we found it consistent with the self-management ethos to use a selfreported measure rather than an objective adherence measure. To achieve enhanced medical adherence, a change-of-behavior approach should probably be considered, as addressed by Hommel et al. 32 The use of various telecommunications tools in the care of children and adolescents with diabetes and asthma has already been evaluated in several reviews. [33] [34] [35] Regardless of the tool (e.g., Mobile phone communication/Remote Disease Monitoring/Phone and Video communication/Smartphone Applications/computerguided education system), the conclusion of 2 reviews 33, 34 was that diabetic telecommunication improves glycemic control (level of HbA1c), but offers a less convincing improvement in diabetes control (adherence to self-monitoring blood glucose). Satisfaction with a telecommunication tool was high, and despite inconsistent measures of "self-management," this item was found to be improved. No adverse events were reported and one study found lower hospitalization rates for diabetic complications. 36 In a very recent study, the use of telemedicine, (eVisit, i.e., a clinical visit performed through a computerized interface, and e-Messaging) allowed more continuous communication and timely follow-ups in pediatric IBD. 14 Even when allowing for the differences between diabetes, asthma, and IBD care, telecommunication and eHealth approaches seem feasible, useful, and safe in the care of children and adolescent patients.
Absence from School
We have assumed that the fewer days of school absence in the eHealth group observed in this study likewise mirrors less absence from social activities. During the study, patients in the control group had more outpatient visits and more hospitalizations than the intervention group; however, this difference does not explain the aforementioned finding alone. Previous adult IBD eHealth 12 and self-management studies 30 have shown that eHealth allows patients to recognize a flare-up and receive adequate and relevant treatment significantly faster than patients receiving standard outpatient care. It should be noted that school absence in our study was self-reported, with a risk of reporting bias, but as both groups self-reported we expect the effect of any such bias to be minimal.
HRQoL
We did not find improvement or deterioration in HRQoL comparing the eHealth with the control group. A recent systematic review of eHealth technologies in adult IBD concluded that QoL improvement has been consistent in the reviewed publications. 37 Compared with adult care, pediatric care has a more tightly controlled strategy as patients are seen in the outpatient clinic with 3 months (pediatric) versus 6-to 12-month intervals or on demand (adult). Furthermore, the pediatric IBD-care team is handled by a few IBD-specialists and IBD-nurses, that is, the family has a close relationship to the IBD-care team. Outpatient visits in pediatric settings are calculated to have a duration of 30 to 60 minutes The patient were seen in the pediatric emergency department but were discharged within the same day. IQR, interquartile range.
compared with 10 to 15 minutes in the adult care set-up. Pediatric care has more financial resources available per patient compared with the adult care, and a further improvement of care and QoL on behalf of eHealth management in pediatric settings may therefore be more difficult to achieve than in adult settings. The fact that we did not find a deterioration in HRQoL in the web group emphasizes that eHealth is not inferior to standard care.
Socioeconomic Perspectives
From a socioeconomic perspective, the reduced school absence and fewer outpatient visits in the web group represent an economic gain, as parents do not require leave from work and it saves the time and expense of travel to/from our hospital (because of the hospital's specialized IBD function covering a large geographic area, patients can spend 1 or 2 hours traveling to the hospital). Patients' improved school attendance might also benefit their educational achievements in the long term. Furthermore, the fewer outpatient visits and the fact that the eHealth tool can be nurse-administered (in cooperation with IBD doctors) allows for a redistribution of doctor consultations to patients with active disease.
Strengths and Limitations
The strength of the study is the use of a novel eHealth application in a challenging patient group, as well as the long follow-up period, which allows the study to reflect the use in a daily, nontrial setting. Patients were included from a public hospital with a dedicated IBD clinic serving patients arriving from a large geographic area and representing a diverse patient population with both severe and mild phenotypes. There is, however, a risk of selection bias, as resourceful families are more likely to participate in trials generally. The study is limited by relatively few participants that were all sourced from one center. The drop out rate during the study was 44% in the web group, 19% before and 26% after 1 year of participation. However, we did not find a difference in time to drop out when comparing the web and control groups. Reasons for drop out were as follows: change to biological treatment (web 4; control 3), wish to withdraw (web 4: control 3), change to adult care (web 1; control 1), unsafe adherence (web 2), lost computer (web 1), and emigration (control 1). The reasons for drop out are highly varied, and no systematical tendency was noted in the web group as compared with the control group. The high drop out rates in both groups may reflect the changeability of circumstances and the difficulties of completing trials among this specific age group. Finally, the study design might have gained from using a noninferior design for the statistical analysis and power calculation.
The concept of the pediatric TIBS is built on the TIBS used in adult eHealth trials. [8] [9] [10] 12 The pediatric TIBS was created for this trial and has not previously been validated, which is a limitation of the study. However, the components of the TIBS-both PUCAI and abbrPCDAI-are internationally accepted and validated disease activity indices, and FC is a well-investigated inflammation marker in the management of IBD. 19, 20 
Perspective
In the long term, eHealth may improve self-management and possibly improve the disease outcome in patients with chronic disease. 30 In line with improved self-management, eHealth monitoring might prepare patients for the transition from pediatric to adult care, where more responsibility and self-care is expected. 38 Future studies will test this hypothesis.
Because of lifestyle during puberty and changing living conditions (e.g., education, traveling, and studying abroad), young patients need a flexible approach to obtaining the best health care. eHealth might offer an important opportunity to the patient to continue effective disease control without compromising a normal way of life. To further address the use of eHealth as a part of their daily IBD care, the eHealth solution www.young. constant-care.com will be implemented as a standard care option in our department. To our knowledge, this is the first implementation of eHealth monitoring as standard care. 37 
CONCLUSIONS
In conclusion, children and adolescents with IBD can manage self-administered eHealth monitoring without risk of increased disease activity or escalated treatment. Medical adherence and HRQoL neither improved nor deteriorated during this study. School absence and costs of care were reduced. Consequently, eHealth can be safely offered to pediatric and adolescent patients with IBD. As the use of eHealth is likely to become an important part of future health care, future studies addressing the use of eHealth in larger and more varied pediatric populations should be conducted.
